Provided by Tiger Trade Technology Pte. Ltd.

Cocrystal Pharma, Inc.

0.9546
-0.0026-0.27%
Post-market: 0.96000.0054+0.57%16:02 EST
Volume:31.34K
Turnover:29.63K
Market Cap:13.16M
PE:-1.02
High:0.9790
Open:0.9626
Low:0.9000
Close:0.9572
52wk High:2.67
52wk Low:0.8588
Shares:13.78M
Float Shares:9.35M
Volume Ratio:0.36
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9317
EPS(LYR):-1.7205
ROE:-94.94%
ROA:-45.77%
PB:1.72
PE(LYR):-0.55

Loading ...

Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares

Reuters
·
Feb 10

Cocrystal Pharma Grants Stock Options to Directors and Executives Under New Equity Plan

Reuters
·
Jan 16

Director and 10% Owner Phillip Frost Reports Acquisition of Cocrystal Pharma Common Shares

Reuters
·
Jan 01

BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine

Reuters
·
Dec 18, 2025

Cocrystal Pharma Receives IRB Approval for Phase 1b Norovirus Study

Reuters
·
Dec 18, 2025

Cocrystal Pharma Receives Irb Approval From Emory University School of Medicine for Phase 1B Human Challenge Study With Cdi-988 for Prevention and Treatment of Norovirus

THOMSON REUTERS
·
Dec 18, 2025

Cocrystal Pharma Inc - Subject Enrollment for Study Expected to Begin in Q1 2026

THOMSON REUTERS
·
Dec 18, 2025

Cocrystal Pharma Inc. unveils investor presentation highlighting advances in broad-spectrum antiviral drug development

Reuters
·
Dec 02, 2025

Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares

Reuters
·
Nov 26, 2025

Cocrystal Pharma Receives FDA Clearance and NIH Grant to Advance Norovirus and Influenza Programs

Reuters
·
Nov 14, 2025

Cocrystal Pharma Q3 loss narrows

Reuters
·
Nov 14, 2025

BRIEF-Cocrystal Pharma Q3 Net Income USD -2.049 Million

Reuters
·
Nov 14, 2025

Cocrystal Pharma Q3 Basic EPS USD -0.19

THOMSON REUTERS
·
Nov 14, 2025

Cocrystal Pharma Inc - Phase 1B Norovirus Study for Cdi-988 Expected in Q1 2026

THOMSON REUTERS
·
Nov 14, 2025

Cocrystal Pharma Q3 Operating Expenses USD 2.089 Million

THOMSON REUTERS
·
Nov 14, 2025

Cocrystal Pharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Oct 30, 2025

Noble Financial Remains a Buy on Cocrystal Pharma (COCP)

TIPRANKS
·
Oct 23, 2025

Cocrystal Pharma Inc publishes investor presentation on advancing broad spectrum antiviral drug candidates for influenza norovirus and coronavirus

Reuters
·
Oct 10, 2025

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

TIPRANKS
·
Sep 20, 2025